0000950170-22-021605 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2022	Oct. 27, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	KURA
Entity Registrant Name	KURA ONCOLOGY, INC.
Entity Central Index Key	0001422143
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		66,896,972
Entity File Number	001-37620
Entity Tax Identification Number	61-1547851
Entity Address, Address Line One	12730 High Bluff Drive
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92130
City Area Code	858
Local Phone Number	500-8800
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 90,937	$ 90,672
Short-term investments	336,838	427,288
Prepaid expenses and other current assets	8,616	4,329
Total current assets	436,391	522,289
Property and equipment, net	2,734	2,673
Restricted cash	210	210
Operating lease right-of-use assets	4,284	5,573
Other long-term assets	4,369	3,306
Total assets	447,988	534,051
Current liabilities:
Accounts payable and accrued expenses	22,441	20,192
Current operating lease liabilities	2,304	2,263
Total current liabilities	24,745	22,455
Long-term operating lease liabilities	3,080	4,612
Other long-term liabilities	542	375
Total liabilities	28,367	27,442
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000 shares authorized; 66,894 and 66,572 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	7	7
Additional paid-in capital	964,724	941,359
Accumulated other comprehensive loss	(9,416)	(1,789)
Accumulated deficit	(535,694)	(432,968)
Total stockholders' equity	419,621	506,609
Total liabilities and stockholders' equity	$ 447,988	$ 534,051

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	66,894,000	66,572,000
Common stock, shares outstanding	66,894,000	66,572,000

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating Expenses:
Research and development	$ 24,973	$ 22,367	$ 70,144	$ 63,765
General and administrative	11,621	11,310	34,565	34,455
Total operating expenses	36,594	33,677	104,709	98,220
Other Income (Expense):
Interest and other income, net	1,090	311	1,983	911
Interest expense				(414)
Total other income, net	1,090	311	1,983	497
Net Loss	$ (35,504)	$ (33,366)	$ (102,726)	$ (97,723)
Net loss per share, basic	$ (0.53)	$ (0.50)	$ (1.54)	$ (1.47)
Net loss per share, diluted	$ (0.53)	$ (0.50)	$ (1.54)	$ (1.47)
Weighted average number of shares used in computing net loss per share, basic	66,889	66,353	66,723	66,285
Weighted average number of shares used in computing net loss per share, diluted	66,889	66,353	66,723	66,285
Comprehensive Loss:
Net loss	$ (35,504)	$ (33,366)	$ (102,726)	$ (97,723)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities and foreign currency	(1,601)	199	(7,627)	(240)
Comprehensive Loss	$ (37,105)	$ (33,167)	$ (110,353)	$ (97,963)

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid- In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 610,905	$ 7	$ 913,354	$ 46	$ (302,502)
Beginning balance (in shares) at Dec. 31, 2020		66,194
Share-based compensation expense	17,182		17,182
Issuance of common stock under equity plans	3,632		3,632
Issuance of common stock under equity plans, shares		310
Other comprehensive income (loss)	(240)			(240)
Net loss	(97,723)				(97,723)
Ending balance at Sep. 30, 2021	533,756	$ 7	934,168	(194)	(400,225)
Ending balance (in shares) at Sep. 30, 2021		66,504
Beginning balance at Jun. 30, 2021	558,551	$ 7	925,796	(393)	(366,859)
Beginning balance (in shares) at Jun. 30, 2021		66,296
Share-based compensation expense	6,114		6,114
Issuance of common stock under equity plans	2,258		2,258
Issuance of common stock under equity plans, shares		208
Other comprehensive income (loss)	199			199
Net loss	(33,366)				(33,366)
Ending balance at Sep. 30, 2021	533,756	$ 7	934,168	(194)	(400,225)
Ending balance (in shares) at Sep. 30, 2021		66,504
Beginning balance at Dec. 31, 2021	506,609	$ 7	941,359	(1,789)	(432,968)
Beginning balance (in shares) at Dec. 31, 2021		66,572
Share-based compensation expense	19,513		19,513
Issuance of common stock under equity plans	3,852		3,852
Issuance of common stock under equity plans, shares		322
Other comprehensive income (loss)	(7,627)			(7,627)
Net loss	(102,726)				(102,726)
Ending balance at Sep. 30, 2022	419,621	$ 7	964,724	(9,416)	(535,694)
Ending balance (in shares) at Sep. 30, 2022		66,894
Beginning balance at Jun. 30, 2022	449,491	$ 7	957,489	(7,815)	(500,190)
Beginning balance (in shares) at Jun. 30, 2022		66,838
Share-based compensation expense	6,355		6,355
Issuance of common stock under equity plans	880		880
Issuance of common stock under equity plans, shares		56
Other comprehensive income (loss)	(1,601)			(1,601)
Net loss	(35,504)				(35,504)
Ending balance at Sep. 30, 2022	$ 419,621	$ 7	$ 964,724	$ (9,416)	$ (535,694)
Ending balance (in shares) at Sep. 30, 2022		66,894

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating Activities
Net loss	$ (102,726)	$ (97,723)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	19,513	17,182
Amortization of premium and accretion of discounts on marketable securities, net	2,264	3,175
Depreciation expense	553	392
Non-cash interest expense		399
Loss on extinguishment of debt		212
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(4,287)	(1,488)
Other long-term assets	226	(746)
Accounts payable and accrued expenses	758	(2,549)
Other long-term liabilities	167	(39)
Net cash used in operating activities	(83,532)	(81,185)
Investing Activities
Maturities of marketable securities	245,091	229,469
Purchases of marketable securities	(164,532)	(429,320)
Purchases of property and equipment	(614)	(1,045)
Net cash provided by (used in) investing activities	79,945	(200,896)
Financing Activities
Proceeds from issuance of stock under equity plans	3,852	3,632
Repayment of long-term debt		(7,250)
Payment of fees related to extinguishment of debt		(611)
Net cash provided by (used in) financing activities	3,852	(4,229)
Net increase (decrease) in cash, cash equivalents and restricted cash	265	(286,310)
Cash, cash equivalents and restricted cash at beginning of period	90,882	325,703
Cash, cash equivalents and restricted cash at end of period	$ 91,147	$ 39,393

Organization and Basis of Presentation

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation

1. Organization and Basis of Presentation

The Company

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule product candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We plan to advance our product candidates through a combination of internal development and strategic partnerships while maintaining significant development and commercial rights.

References in these Notes to Unaudited Condensed Financial Statements to the “Company,” “we,” “our” or “us,” refer to Kura Oncology, Inc.

Basis of Presentation

The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on February 24, 2022, from which we derived our balance sheet as of December 31, 2021. The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited condensed financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

The preparation of the unaudited condensed financial statements in accordance with GAAP requires our management to make estimates and assumptions that affect the amounts reported on our unaudited condensed financial statements and accompanying notes. The amounts reported could differ under different estimates and assumptions. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

The extent to which the COVID-19 pandemic has impacted and may continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted with any confidence, such as the duration and severity of the COVID-19 pandemic, steps required or mandated by governments to mitigate the impact of COVID-19 or the effectiveness of actions to prevent, contain and treat COVID-19, particularly in the geographies where we, our third-party manufacturers, contract research organizations or current and planned clinical trial sites operate. We cannot presently predict the scope and severity of any potential business disruptions, interruptions or shutdowns. If we or any of the third parties with whom we engage, however, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial condition.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Reclassifications

Certain prior period balances have been reclassified to conform to the current period presentation.

Restricted Cash

Under the terms of an office lease entered into in March 2020, we are required to maintain a standby letter of credit during the term of the lease. As of September 30, 2022, restricted cash of $0.2 million was pledged as collateral for the letter of credit.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed balance sheets that sum to the total of the amounts shown in the unaudited condensed statements of cash flows, in thousands:


	September 30, 2022		December 31, 2021		September 30, 2021		December 31, 2020
Cash and cash equivalents	$	90,937	$	90,672	$	39,183	$	325,493
Restricted cash		210		210		210		210
Total	$	91,147	$	90,882	$	39,393	$	325,703

Allowance for Credit Losses

For available-for-sale securities in an unrealized loss position, we first assess whether we intend to sell, or if it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive income (loss) on the unaudited condensed statements of operations and comprehensive loss.

We elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of our available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded within prepaid expenses and other current assets on our unaudited condensed balance sheets. Our accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us.

Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

Net Loss per Share

Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock method. As we have reported net loss for the three and nine months ended September 30, 2022 and 2021, dilutive net loss per common share is the same as basic net loss per common share for those periods. Common stock equivalents outstanding are comprised of stock options, restricted stock units, a warrant and employee stock purchase plan rights and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Common stock equivalents outstanding at September 30, 2022 and 2021 totaling approximately 9,111,000 and 6,950,000, respectively, were excluded from the computation of dilutive weighted-average shares outstanding because their effect would be anti-dilutive.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. We have evaluated recently issued accounting pronouncements and, based on our preliminary assessment, we do not believe any will have a material impact on our unaudited condensed financial statements or related footnote disclosures.

Investments

9 Months Ended

Sep. 30, 2022

Investments, All Other Investments [Abstract]

Investments

3. Investments

We invest in available-for-sale securities consisting of money market funds, U.S. Treasury securities, corporate debt securities, commercial paper, non-U.S. government debt securities, supranational debt securities and U.S. Agency bonds. Available-for-sale securities are classified as either cash and cash equivalents or short-term investments on our unaudited condensed balance sheets.

The following tables summarize, by major security type, our short-term investments that are measured at fair value on a recurring basis, in thousands:


		September 30, 2022
	Maturities (years)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Cash equivalents:
Money market funds	1 or less	$	80,905	$	—	$	—		$	80,905

Short-term investments:
U.S. Treasury securities	2 or less		146,343		—		(3,403	)		142,940
Corporate debt securities	2 or less		126,894		—		(4,687	)		122,207
Commercial paper	1 or less		37,718		—		—			37,718
Non-U.S. government and supranational debt securities	2 or less		26,302		—		(1,089	)		25,213
U.S. Agency bonds	1 or less		8,997		—		(237	)		8,760
Total short-term investments			346,254		—		(9,416	)		336,838
Total		$	427,159	$	—	$	(9,416	)	$	417,743


		December 31, 2021
	Maturities (years)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Cash equivalents:
Money market funds	1 or less	$	79,895	$	—	$	—		$	79,895

Short-term investments:
U.S. Treasury securities	3 or less		135,452		—		(619	)		134,833
Corporate debt securities	3 or less		208,064		—		(892	)		207,172
Commercial paper	1 or less		53,439		—		—			53,439
Non-U.S. government and supranational debt securities	3 or less		23,122		—		(214	)		22,908
U.S. Agency bonds	2 or less		8,994		—		(58	)		8,936
Total short-term investments			429,071		—		(1,783	)		427,288
Total		$	508,966	$	—	$	(1,783	)	$	507,183

Short-term investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund our operations, as necessary. As of September 30, 2022 and December 31, 2021, short-term investments of $179.2 million and $246.9 million, respectively, had maturities less than one year, and short-term investments of $157.6 million and $180.4 million, respectively, had maturities between one to three years. We had no realized gains or losses for the nine months ended September 30, 2022 and 2021.

As of September 30, 2022, 35 available-for-sale securities with a fair market value of $299.1 million were in gross unrealized loss positions, $110.6 million of which were in a continuous unrealized loss position for greater than 12 months. We do not intend to sell these available-for-sale securities, and it is not more likely than not that we will be required to sell these securities prior to recovery of their amortized cost basis. Based on our review of these available-for-sale securities, the unrealized losses at September 30, 2022 were primarily due to changes in interest rates and not due to increased credit risks associated with specific securities. We have no allowance for credit losses as of September 30, 2022 and December 31, 2021. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive (income) loss.

Accrued interest receivable on available-for-sale securities was $1.1 million and $1.4 million at September 30, 2022 and December 31, 2021, respectively. We have not written off any accrued interest receivables for the nine months ended September 30, 2022 and 2021.

Fair Value Measurements

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

As of September 30, 2022 and December 31, 2021, we had cash equivalents and short-term investments measured at fair value on a recurring basis.

Available-for-sale securities consist of U.S. Treasury securities, which are measured at fair value using Level 1 inputs, and corporate debt securities, commercial paper, non-U.S. government debt securities, supranational debt securities and U.S. Agency bonds which are measured at fair value using Level 2 inputs. We determine the fair value of Level 2 related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We validate the fair values of Level 2 financial instruments by comparing these fair values to a third-party pricing source.

The following tables summarize, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy, in thousands:


	September 30, 2022
	Total		Level 1		Level 2
Cash equivalents:
Money market funds	$	80,905	$	80,905	$	—

Short-term investments:
U.S. Treasury securities		142,940		142,940		—
Corporate debt securities		122,207	—			122,207
Commercial paper		37,718	—			37,718
Non-U.S. government and supranational debt securities		25,213		—		25,213
U.S. Agency bonds		8,760		—		8,760
Total short-term investments		336,838		142,940		193,898
Total	$	417,743	$	223,845	$	193,898


	December 31, 2021
	Total		Level 1		Level 2
Cash equivalents:
Money market funds	$	79,895	$	79,895	$	—

Short-term investments:
U.S. Treasury securities		134,833		134,833		—
Corporate debt securities		207,172	—			207,172
Commercial paper		53,439	—			53,439
Non-U.S. government and supranational debt securities		22,908		—		22,908
U.S. Agency bonds		8,936		—		8,936
Total short-term investments		427,288		134,833		292,455
Total	$	507,183	$	214,728	$	292,455

Balance Sheet Detail

9 Months Ended

Sep. 30, 2022

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Detail

5. Balance Sheet Detail

Property and equipment consisted of the following, in thousands:


	September 30, 2022			December 31, 2021
Laboratory and computer equipment	$	1,556		$	953
Leasehold improvements		1,543			1,532
Furniture and fixtures		1,032			1,032
Property and equipment, gross		4,131			3,517
Less: accumulated depreciation		(1,397	)		(844	)
Property and equipment, net	$	2,734		$	2,673

Accounts payable and accrued expenses consisted of the following, in thousands:


	September 30, 2022		December 31, 2021
Accounts payable	$	1,746	$	3,236
Accrued clinical trial research and development expenses		5,471		2,619
Accrued other research and development expenses		5,400		5,341
Accrued compensation and benefits		7,966		7,923
Other accrued expenses		1,858		1,073
Total accounts payable and accrued expenses	$	22,441	$	20,192

Leases

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Leases

6. Leases

We currently have three operating leases for administrative and research and development office and lab space in San Diego, California and Boston, Massachusetts that expire between July 2024 and November 2025. Under the terms of the operating leases, we are required to pay our proportionate share of property taxes, insurance and normal maintenance costs. Two of our leases include renewal options for an additional five years, which were not included in the determination of the right-of-use, or ROU, asset or lease liability as the renewal was not reasonably certain at the inception of the lease. Our San Diego corporate headquarters lease and our San Diego lease for lab and office space provided for $1.0 million and $0.1 million, respectively, in reimbursements for allowable tenant improvements, which effectively reduced the total lease payments owed. Under the terms of our office lease in Boston, we are required to maintain a standby letter of credit of approximately $0.2 million during the term of the lease.

Maturities of lease liabilities as of September 30, 2022 are as follows, in thousands:


Year Ending December 31,
2022 (remaining)	$	586
2023		2,375
2024		1,863
2025		929
Total lease payments		5,753
Less: imputed interest		(369	)
Total operating lease liabilities	$	5,384

As of September 30, 2022 and December 31, 2021, the weighted-average discount rate was 5.5% for both periods, and the weighted-average remaining lease term was 2.6 years and 3.3 years, respectively. Total cash paid for amounts included in the measurement of operating lease liabilities was $1.7 million and $1.5 million for the nine months ended September 30, 2022 and 2021, respectively. There were no operating lease ROU assets obtained in exchange for operating lease liabilities for the nine months ended September 30, 2022 and 2021. Total operating lease expense for the three months ended September 30, 2022 and 2021 was approximately $0.5 million in both periods. Total operating lease expense for the nine months ended September 30, 2022 and 2021 was approximately $1.5 million in both periods.

Stockholders' Equity

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Stockholders' Equity

7. Stockholders’ Equity

In February 2022, we terminated the Common Stock Sales Agreement with SVB Leerink LLC and Stifel, Nicolaus & Company, Incorporated and entered into a new Common Stock Sales Agreement with SVB Securities LLC, Credit Suisse Securities (USA) LLC and Cantor Fitzgerald & Co., or the ATM Facility, under which we may offer and sell, from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $150.0 million. We have not sold any shares of our common stock under the ATM Facility.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Share-Based Compensation

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation

8. Share-Based Compensation

The following table summarizes share-based compensation expense for all share-based compensation arrangements, in thousands:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2022		2021		2022		2021
Research and development	$	2,492	$	2,059	$	7,545	$	5,277
General and administrative		3,863		4,055		11,968		11,905
Total share-based compensation expense	$	6,355	$	6,114	$	19,513	$	17,182

As of September 30, 2022, unrecognized estimated compensation expense related to stock options and restricted stock units was approximately $48.4 million and $10.8 million, respectively, which is expected to be recognized over a weighted average period of approximately 2.6 years for both stock options and restricted stock units.

Subsequent Events

9 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

Subsequent Events

9. Subsequent Events

Loan and Security Agreement

On November 2, 2022, we entered into a loan and security agreement, or Loan Agreement, with several banks and other financial institutions or entities party thereto, or collectively Lenders, and Hercules Capital, Inc., or Hercules, in its capacity as administrative agent and collateral agent for itself and the Lenders, or in such capacity, Agent. Under the terms of the Loan Agreement, we borrowed $10.0 million of an initial $25.0 million tranche of term loans, or the Tranche 1 Loan, and we may, at our sole discretion, borrow the remaining $15.0 million in respect of the Tranche 1 Loan at any time until September 15, 2023. Thereafter, we may borrow (i) additional tranches of term loans in the amounts of up to $35.0 million, or the Tranche 2 Loan, and $40.0 million, or the Tranche 3 Loan, respectively, which will become available to us upon our satisfaction of certain terms and conditions set forth in the Loan Agreement, and (ii) a final tranche of term loans in the amount of up to $25.0 million, or the Tranche 4 Loan, subject to the Lenders’ investment committee approval in its sole discretion. All of the Term Loans have a maturity date of November 2, 2027, or the Maturity Date. Repayment of the Term Loans is interest only through (a) initially, November 1, 2024, (b) if we satisfy the Interest Only Milestone 1 Conditions (as defined in the Loan Agreement), May 1, 2025, (c) if we satisfy the Interest Only Milestone 2 Conditions (as defined in the Loan Agreement), November 1, 2025, and (d) if we satisfy the Approval Milestone (as defined in the Loan Agreement), November 1, 2026. After the interest-only payment period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. The per annum interest rate for the Term Loans is the greater of (i) the prime rate as reported in The Wall Street Journal minus 6.25% plus 8.65% and (ii) 8.65%.

At our option, we may prepay all or any portion of the outstanding Term Loans at any time. Prepayments made on or prior to the third anniversary of the date of the Loan Agreement will be subject to a prepayment fee equal to 1.50% of the principal amount being prepaid. In addition, we paid a $125,000 facility charge upon closing and will pay additional facility charges in connection with any borrowing of the Tranche 2 Loan, Tranche 3 Loan or Tranche 4 Loan, in each case in the amount of 0.50% of the amount of such tranche of loans. The Loan Agreement also provides for an end of term fee in an amount equal to the greater of (i) $1,512,500 (which is 6.05% of the maximum amount of the first tranche of loans) or (ii) 6.05% of the aggregate principal amount of loan advances actually made under the Loan Agreement, which fee is due and payable on the earliest to occur of (i) the Maturity Date, (ii) the date we prepay the outstanding loans in full, and (iii) the date that the secured obligations become due and payable. Our obligations under the Loan Agreement are secured by substantially all of our assets other than our intellectual property, but including proceeds from the sale, licensing or other disposition of our intellectual property. Our intellectual property is subject to negative covenants, which, among other things, prohibit us from selling, transferring, assigning, mortgaging, pledging, leasing, granting a security interest in or otherwise encumbering our intellectual property, subject to limited exceptions.

In addition, in connection with the entry into the Loan Agreement, we issued warrants to certain of the Lenders, or collectively, the Warrants, to acquire up to 26,078 shares of our common stock at an exercise price of $14.38 per share, or the Warrant Shares. The Warrants may be exercised through the earlier of (i) the seventh anniversary of November 2, 2022 and (ii) the consummation of certain acquisition transactions involving us, as set forth in the Warrants. The number of Warrant Shares for which the Warrants are exercisable and the associated exercise price are subject to certain customary proportional adjustments for fundamental events, including stock splits and reverse stock splits, as set forth in the Warrants. If we make additional draws on the Tranche 2 Loan, Tranche 3 Loan or Tranche 4 Loan, upon the funding of such additional tranches, the Warrants shall become exercisable for an additional aggregate number of shares of our common stock equal to 1.50% of each drawn amount divided by $14.38 per share, the exercise price per share.

Securities Purchase Agreement

On November 2, 2022, we entered into a securities purchase agreement with Bristol-Myers Squibb Company, or BMS, pursuant to which BMS has agreed to purchase an aggregate of 1,370,171 shares of common stock in a registered direct offering, at a purchase price of approximately $18.25 per share, for gross proceeds of approximately $25.0 million. The BMS Offering is anticipated to close on or about November 3, 2022.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Reclassifications

Certain prior period balances have been reclassified to conform to the current period presentation.

Restricted Cash


	September 30, 2022		December 31, 2021		September 30, 2021		December 31, 2020
Cash and cash equivalents	$	90,937	$	90,672	$	39,183	$	325,493
Restricted cash		210		210		210		210
Total	$	91,147	$	90,882	$	39,393	$	325,703

Allowance for Credit Losses on Available-for-Sale Debt Securities

Allowance for Credit Losses

Concentration of Credit Risk

Net Loss per Share

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash


	September 30, 2022		December 31, 2021		September 30, 2021		December 31, 2020
Cash and cash equivalents	$	90,937	$	90,672	$	39,183	$	325,493
Restricted cash		210		210		210		210
Total	$	91,147	$	90,882	$	39,393	$	325,703

Investments (Tables)

9 Months Ended

Sep. 30, 2022

Investments, All Other Investments [Abstract]

Investments Measured at Fair Value on Recurring Basis

The following tables summarize, by major security type, our short-term investments that are measured at fair value on a recurring basis, in thousands:


		September 30, 2022
	Maturities (years)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Cash equivalents:
Money market funds	1 or less	$	80,905	$	—	$	—		$	80,905

Short-term investments:
U.S. Treasury securities	2 or less		146,343		—		(3,403	)		142,940
Corporate debt securities	2 or less		126,894		—		(4,687	)		122,207
Commercial paper	1 or less		37,718		—		—			37,718
Non-U.S. government and supranational debt securities	2 or less		26,302		—		(1,089	)		25,213
U.S. Agency bonds	1 or less		8,997		—		(237	)		8,760
Total short-term investments			346,254		—		(9,416	)		336,838
Total		$	427,159	$	—	$	(9,416	)	$	417,743


		December 31, 2021
	Maturities (years)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Cash equivalents:
Money market funds	1 or less	$	79,895	$	—	$	—		$	79,895

Short-term investments:
U.S. Treasury securities	3 or less		135,452		—		(619	)		134,833
Corporate debt securities	3 or less		208,064		—		(892	)		207,172
Commercial paper	1 or less		53,439		—		—			53,439
Non-U.S. government and supranational debt securities	3 or less		23,122		—		(214	)		22,908
U.S. Agency bonds	2 or less		8,994		—		(58	)		8,936
Total short-term investments			429,071		—		(1,783	)		427,288
Total		$	508,966	$	—	$	(1,783	)	$	507,183

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule Of Fair Value Measurements, By Major Security Type


	September 30, 2022
	Total		Level 1		Level 2
Cash equivalents:
Money market funds	$	80,905	$	80,905	$	—

Short-term investments:
U.S. Treasury securities		142,940		142,940		—
Corporate debt securities		122,207	—			122,207
Commercial paper		37,718	—			37,718
Non-U.S. government and supranational debt securities		25,213		—		25,213
U.S. Agency bonds		8,760		—		8,760
Total short-term investments		336,838		142,940		193,898
Total	$	417,743	$	223,845	$	193,898


	December 31, 2021
	Total		Level 1		Level 2
Cash equivalents:
Money market funds	$	79,895	$	79,895	$	—

Short-term investments:
U.S. Treasury securities		134,833		134,833		—
Corporate debt securities		207,172	—			207,172
Commercial paper		53,439	—			53,439
Non-U.S. government and supranational debt securities		22,908		—		22,908
U.S. Agency bonds		8,936		—		8,936
Total short-term investments		427,288		134,833		292,455
Total	$	507,183	$	214,728	$	292,455

Balance Sheet Detail (Tables)

9 Months Ended

Sep. 30, 2022

Balance Sheet Related Disclosures [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following, in thousands:


	September 30, 2022			December 31, 2021
Laboratory and computer equipment	$	1,556		$	953
Leasehold improvements		1,543			1,532
Furniture and fixtures		1,032			1,032
Property and equipment, gross		4,131			3,517
Less: accumulated depreciation		(1,397	)		(844	)
Property and equipment, net	$	2,734		$	2,673

Summary of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following, in thousands:


	September 30, 2022		December 31, 2021
Accounts payable	$	1,746	$	3,236
Accrued clinical trial research and development expenses		5,471		2,619
Accrued other research and development expenses		5,400		5,341
Accrued compensation and benefits		7,966		7,923
Other accrued expenses		1,858		1,073
Total accounts payable and accrued expenses	$	22,441	$	20,192

Leases (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Schedule of Maturities of Lease Liabilities

Maturities of lease liabilities as of September 30, 2022 are as follows, in thousands:


Year Ending December 31,
2022 (remaining)	$	586
2023		2,375
2024		1,863
2025		929
Total lease payments		5,753
Less: imputed interest		(369	)
Total operating lease liabilities	$	5,384

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Summary of Share-based Compensation Expense

The following table summarizes share-based compensation expense for all share-based compensation arrangements, in thousands:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2022		2021		2022		2021
Research and development	$	2,492	$	2,059	$	7,545	$	5,277
General and administrative		3,863		4,055		11,968		11,905
Total share-based compensation expense	$	6,355	$	6,114	$	19,513	$	17,182

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Restricted cash pledged as collateral	$ 210	$ 210	$ 210	$ 210
Total potentially dilutive securities	9,111,000	6,950,000
Collateral Pledged
Summary Of Significant Accounting Policies [Line Items]
Restricted cash pledged as collateral	$ 200

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 90,937	$ 90,672	$ 39,183	$ 325,493
Restricted cash	210	210	210	210
Total	$ 91,147	$ 90,882	$ 39,393	$ 325,703

Investments - Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Fair Value	$ 336,838	$ 427,288
Fair Value Measurements on Recurring Basis
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	346,254	429,071
Short-term investments, Unrealized Losses	(9,416)	(1,783)
Short-term investments, Fair Value	336,838	427,288
Cash equivalents and Short-term investments, Amortized Cost	427,159	508,966
Cash equivalents and Short-term investments, Unrealized Losses	(9,416)	(1,783)
Cash equivalents and Short-term investments, Estimated Fair Value	$ 417,743	$ 507,183
Fair Value Measurements on Recurring Basis \| Money Market Funds
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	1 or less	1 or less
Cash equivalents, Amortized Cost	$ 80,905	$ 79,895
Cash equivalents, Fair Value	80,905	79,895
Fair Value Measurements on Recurring Basis \| U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	146,343	135,452
Short-term investments, Unrealized Losses	(3,403)	(619)
Short-term investments, Fair Value	$ 142,940	$ 134,833
Fair Value Measurements on Recurring Basis \| U.S. Treasury Securities \| Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	2 years	3 years
Fair Value Measurements on Recurring Basis \| Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	$ 126,894	$ 208,064
Short-term investments, Unrealized Losses	(4,687)	(892)
Short-term investments, Fair Value	$ 122,207	$ 207,172
Fair Value Measurements on Recurring Basis \| Corporate Debt Securities \| Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	2 years	3 years
Fair Value Measurements on Recurring Basis \| Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	$ 37,718	$ 53,439
Short-term investments, Fair Value	$ 37,718	$ 53,439
Fair Value Measurements on Recurring Basis \| Commercial Paper \| Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	1 year	1 year
Fair Value Measurements on Recurring Basis \| Non U S Government And Supranational Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	$ 26,302	$ 23,122
Short-term investments, Unrealized Losses	(1,089)	(214)
Short-term investments, Fair Value	$ 25,213	$ 22,908
Fair Value Measurements on Recurring Basis \| Non U S Government And Supranational Debt Securities \| Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	2 years	3 years
Fair Value Measurements on Recurring Basis \| U.S. Agency Bonds
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	$ 8,997	$ 8,994
Short-term investments, Unrealized Losses	(237)	(58)
Short-term investments, Fair Value	$ 8,760	$ 8,936
Fair Value Measurements on Recurring Basis \| U.S. Agency Bonds \| Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	1 year	2 years

Investments - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) Security	Dec. 31, 2021 USD ($)
Investments, All Other Investments [Abstract]
Short-term investments with maturities less than one year	$ 179,200	$ 246,900
Short-term investments with maturities between one to three years	$ 157,600	180,400
Short-term investments maturities, description	As of September 30, 2022 and December 31, 2021, short-term investments of $179.2 million and $246.9 million, respectively, had maturities less than one year, and short-term investments of $157.6 million and $180.4 million, respectively, had maturities between one to three years.
Allowance for credit losses	$ 0	0
Available for sale securities gross unrealized loss positions	299,100
Available for sale securities gross unrealized loss positions greater than 12 months	$ 110,600
Number of available-for-sale securities \| Security	35
Accrued interest receivable on available-for-sale securities	$ 1,100	$ 1,400

Fair Value Measurements - Schedule Of Fair Value Measurements, By Major Security Type (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	$ 336,838	$ 427,288
Fair Value Measurements on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	336,838	427,288
Cash equivalents and short-term investments	417,743	507,183
Fair Value Measurements on Recurring Basis \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	142,940	134,833
Cash equivalents and short-term investments	223,845	214,728
Fair Value Measurements on Recurring Basis \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	193,898	292,455
Cash equivalents and short-term investments	193,898	292,455
Fair Value Measurements on Recurring Basis \| Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	80,905	79,895
Fair Value Measurements on Recurring Basis \| Money Market Funds \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	80,905	79,895
Fair Value Measurements on Recurring Basis \| U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	142,940	134,833
Fair Value Measurements on Recurring Basis \| U.S. Treasury Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	142,940	134,833
Fair Value Measurements on Recurring Basis \| Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	122,207	207,172
Fair Value Measurements on Recurring Basis \| Corporate Debt Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	122,207	207,172
Fair Value Measurements on Recurring Basis \| Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	37,718	53,439
Fair Value Measurements on Recurring Basis \| Commercial Paper \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	37,718	53,439
Fair Value Measurements on Recurring Basis \| Non U S Government And Supranational Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	25,213	22,908
Fair Value Measurements on Recurring Basis \| Non U S Government And Supranational Debt Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	25,213	22,908
Fair Value Measurements on Recurring Basis \| U S Agency Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	8,760	8,936
Fair Value Measurements on Recurring Basis \| U S Agency Bonds \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	$ 8,760	$ 8,936

Balance Sheet Detail - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4,131	$ 3,517
Less: accumulated depreciation	(1,397)	(844)
Property and equipment, net	2,734	2,673
Laboratory and Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,556	953
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,543	1,532
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,032	$ 1,032

Balance Sheet Detail - Summary of Current Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Accounts payable	$ 1,746	$ 3,236
Accrued clinical trial research and development expenses	5,471	2,619
Accrued other research and development expenses	5,400	5,341
Accrued compensation and benefits	7,966	7,923
Other accrued expenses	1,858	1,073
Total accounts payable and accrued expenses	$ 22,441	$ 20,192

Leases - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
Leases - Additional Information (Detail) - USD ($)	May 31, 2020	Mar. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	May 31, 2022	Dec. 31, 2021
Lessee Lease Description [Line Items]
Lessee, operating lease, expiration period					We currently have three operating leases for administrative and research and development office and lab space in San Diego, California and Boston, Massachusetts that expire between July 2024 and November 2025.
Lease option to extend, description					Two of our leases include renewal options for an additional five years, which were not included in the determination of the right-of-use, or ROU, asset or lease liability as the renewal was not reasonably certain at the inception of the lease
Weighted-average discount rate			5.50%		5.50%			5.50%
Weighted-average remaining lease term			2 years 7 months 6 days		2 years 7 months 6 days			3 years 3 months 18 days
Total cash paid for amounts included in the measurement of lease liabilities					$ 1,700,000	$ 1,500,000
ROU assets obtained in exchange for operating lease liabilities					0	0
ASC 842
Lessee Lease Description [Line Items]
Total operating lease rent expense			$ 500,000	$ 500,000	1,500,000	$ 1,500,000
San Diego Corporate Headquarters Lease
Lessee Lease Description [Line Items]
Operating lease, existence of option to extend		true
Lease agreement additional extended lease term	5 years
Tenant improvement allowance	$ 1,000,000.0
San Diego Lease for Lab and Office Space
Lessee Lease Description [Line Items]
Tenant improvement allowance							$ 100,000
Office Lease in Boston \| Letter of Credit
Lessee Lease Description [Line Items]
Letter of Credit			$ 200,000		$ 200,000
Boston Lease
Lessee Lease Description [Line Items]
Operating lease, existence of option to extend	true
Lease agreement additional extended lease term		5 years

Leases - Schedule of Maturities of Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
2022 (remaining)	$ 586
2023	2,375
2024	1,863
2025	929
Total lease payments	5,753
Less: imputed interest	(369)
Operating Lease Liability	$ 5,384

Stockholder's Equity - Additional Information (Detail) - SVB Securities LLC, Credit Suisse Securities (USA) LLC and Cantor Fitzgerald & Co. - ATM Facility - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Feb. 28, 2022	Sep. 30, 2022
Class of Stock [Line Items]
Common stock, shares issued		0
Maximum
Class of Stock [Line Items]
Aggregate offering price	$ 150.0

Share-Based Compensation - Summary of Share-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 6,355	$ 6,114	$ 19,513	$ 17,182
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	2,492	2,059	7,545	5,277
General and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 3,863	$ 4,055	$ 11,968	$ 11,905

Share-Based Compensation - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized estimated stock option compensation expenses	$ 48.4
Weighted average service period	2 years 7 months 6 days
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized estimated restricted stock units compensation expenses	$ 10.8
Weighted average service period	2 years 7 months 6 days

Subsequent Events - Additional Information (Details) - USD ($)		9 Months Ended
	Nov. 02, 2022	Sep. 30, 2022
Securities Purchase Agreement
Subsequent Event [Line Items]
Stock offering, Transaction date		Nov. 03, 2022
Term Loan \| Loan and Security Agreement
Subsequent Event [Line Items]
Tranche 1 availability end date		Nov. 02, 2027
Principal and interest payments start date		Nov. 01, 2024
Term loan facility per annum interest rate terms		The per annum interest rate for the Term Loans is the greater of (i) the prime rate as reported in The Wall Street Journal minus 6.25% plus 8.65% and (ii) 8.65%.
Interest Only Milestone 1 Conditions \| Loan and Security Agreement
Subsequent Event [Line Items]
Repayment of term loan facility start date		May 01, 2025
Interest Only Milestone 2 Conditions \| Loan and Security Agreement
Subsequent Event [Line Items]
Repayment of term loan facility start date		Nov. 01, 2025
Approval Milestone \| Loan and Security Agreement
Subsequent Event [Line Items]
Repayment of term loan facility start date		Nov. 01, 2026
Subsequent Event \| Loan and Security Agreement
Subsequent Event [Line Items]
Warrant issued	26,078
Warrants exercisable exercise price	$ 14.38
Subsequent Event \| Securities Purchase Agreement
Subsequent Event [Line Items]
Common stock, shares issued	1,370,171
Common stock, issued price per share	$ 18.25
Proceeds from issuances of common stock, gross	$ 25,000,000.0
Subsequent Event \| Tranche 1 Loan \| Loan and Security Agreement
Subsequent Event [Line Items]
Maximum borrowing capacity under term loans	25,000,000.0
Remaining borrowing capacity under term loans	$ 15,000,000.0
Tranche 1 availability end date	Sep. 15, 2023
Subsequent Event \| Tranche 1 draw \| Loan and Security Agreement
Subsequent Event [Line Items]
Principal amount outstanding on loan	$ 10,000,000.0
Subsequent Event \| Tranche 2 Loan \| Loan and Security Agreement
Subsequent Event [Line Items]
Maximum borrowing capacity under term loans	35,000,000.0
Subsequent Event \| Tranche 3 Loan \| Loan and Security Agreement
Subsequent Event [Line Items]
Maximum borrowing capacity under term loans	40,000,000.0
Subsequent Event \| Tranche 4 Loan \| Loan and Security Agreement
Subsequent Event [Line Items]
Maximum borrowing capacity under term loans	$ 25,000,000.0
Subsequent Event \| Additional Tranche \| Loan and Security Agreement
Subsequent Event [Line Items]
Warrants exercisable exercise price	$ 14.38
Percentage of additional warrant	1.50%
Subsequent Event \| Term Loan \| Loan and Security Agreement
Subsequent Event [Line Items]
Commitment fees	$ 125,000
Percentage of prepayment fee to be paid due to early payment	1.50%
Percentage of facility charge	0.50%
Final payment	$ 1,512,500
Final payment percentage	6.05%
Subsequent Event \| Term Loan \| Loan and Security Agreement \| Maximum
Subsequent Event [Line Items]
Final payment percentage	6.05%